<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735667</url>
  </required_header>
  <id_info>
    <org_study_id>S2408</org_study_id>
    <nct_id>NCT03735667</nct_id>
  </id_info>
  <brief_title>ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement</brief_title>
  <official_title>ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve Through Implantation of ACURATE in Subjects InDicatEd for TAVR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for
      transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis
      who are indicated for TAVR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be enrolled at up to 65 centers in the United States and Canada. There will be
      up to 630 subjects in ACURATE IDE.

      The ACURATE IDE study cohorts include the following.

        -  Randomized Cohort: A prospective, multicenter, 1:1 randomized controlled trial (RCT;
           ACURATE versus a commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart
           Valve or future iteration [SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA] or a
           commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement
           System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future
           iteration [CoreValve; Medtronic, Inc., Dublin, Ireland]). There will be up to 500
           subjects in the RCT.

        -  Roll-In Cohort: A non-randomized roll-in phase with the test device. Centers that do not
           have implantation experience with the ACURATE neo™ Aortic Bioprosthesis (transfemoral
           delivery; Symetis SA, Ecublens, Switzerland) will perform at least 2 roll-in cases
           before commencing treatment in the randomized cohort. Centers with prior experience with
           ACURATE are not required to do roll-in cases. Data from roll-in subjects will be
           summarized separately from the randomized cohort and will not be included in the primary
           endpoint analysis.

      All subjects implanted will be followed at baseline, peri- and post-procedure, at discharge
      or 7 days post-procedure (whichever comes first), 30 days, 6 months, and then annually for up
      to 10 years post-procedure. Enrolled subjects who do not have a study device implanted will
      be assessed through 1-year post-procedure for safety/adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">November 2030</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of all-cause mortality, all stroke, life-threatening and major bleeding, stage 2 and 3 acute kidney injury and major vascular complications at 30 days.</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days</time_frame>
    <description>Primary Safety Endpoint; A Clinical Events Committee (CEC), independent group of physician experts was used to evaluate all reported cases of death, stroke, life-threatening and major bleeding, stage 2 and 3 acute kidney injury and major vascular complications to determine whether they met the specific protocol definition of the event. It is the CEC adjudicated result that is used in the endpoint analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of all-cause mortality and disabling stroke at 1 year.</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 1 year</time_frame>
    <description>Primary Effectiveness Endpoint; A Clinical Events Committee (CEC), independent group of physician experts was used to evaluate all reported cases of death and disabling stroke to determine whether they met the specific protocol definition of the event. It is the CEC adjudicated result that is used in the endpoint analysis.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Mortality: all-cause, cardiovascular, and non-cardiovascular</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke: disabling and non-disabling</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction (MI): periprocedural (≤72 hours post index procedure) and spontaneous (&gt;72 hours post index procedure)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding: life-threatening (or disabling) and major</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4 and 5 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Major vascular complications</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4 and 5 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with a repeat procedure for valve-related dysfunction (surgical or interventional therapy)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants with hospitalization for valve-related symptoms or worsening congestive heart failure (NYHA class III or IV)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with new permanent pacemaker implantation resulting from new or worsened conduction disturbances</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with new onset of atrial fibrillation or atrial flutter</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Acute kidney injury (AKI; ≤7 days post index procedure): based on the AKIN System Stage 3 (including renal replacement therapy) or Stage 2</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 7 days post index procedure.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Coronary obstruction: periprocedural</measure>
    <time_frame>Participants will be followed through 72 hours post index procedure</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Ventricular septal perforation</measure>
    <time_frame>Participants will be followed through 72 hours post index procedure</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Mitral apparatus damage: periprocedural</measure>
    <time_frame>Participants will be followed through 72 hours post index procedure</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Cardiac tamponade: periprocedural</measure>
    <time_frame>Participants will be followed through 72 hours post index procedure</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Valve migration</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Valve embolization</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Ectopic valve deployment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Transcatheter aortic valve (TAV)-in-TAV deployment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Prosthetic aortic valve thrombosis</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Prosthetic aortic valve endocarditis</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Successful vascular access, delivery and deployment of the study valve, and successful retrieval of the delivery system (site reported assessment)</measure>
    <time_frame>Participants will be followed for the duration of their procedure, an expected average of 1 day (peri- and post-procedure)</time_frame>
    <description>Device Performance endpoint, as measured by site reported data</description>
  </other_outcome>
  <other_outcome>
    <measure>Grade of aortic valve regurgitation: paravalvular, central and combined (echocardiographic assessment)</measure>
    <time_frame>Participants will be followed for the duration of their procedure, an expected average of 1 day (peri- and post-procedure)</time_frame>
    <description>Device Performance endpoint, as assessed by Echocardiographic Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Device Success</measure>
    <time_frame>Participants will be followed for the duration of their procedure, an expected average of 1 day (post-procedure)</time_frame>
    <description>Absence of procedural mortality, correct positioning of a single transcatheter valve in the proper anatomical location, and intended performance of the study device (indexed effective orifice area [iEOA] &gt;0.85 cm2/m2 for BMI &lt;30 kg/cm2 and iEOA &gt;0.70 cm2/m2 for BMI ≥30 kg/cm2 plus either a mean aortic valve gradient &lt;20 mm Hg or a peak velocity &lt; 3m/sec, and no moderate or severe prosthetic valve aortic regurgitation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Effective Orifice Area (EOA</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Effective Orifice Area (EOA), as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Mean Aortic Gradient</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Mean aortic gradient as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Peak Aortic Gradient</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Peak Aortic Gradient as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Peak Aortic Velocity</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Peak Aortic Velocity as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Grade of Aortic Regurgitation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Grade of Aortic Regurgitation as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) Functional Status classification</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Evaluated by New York Heart Association (NYHA) classification</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological status; National Institutes of Health Stroke Scale (NIHSS) Assessment</measure>
    <time_frame>Participants will be followed at discharge and 1 year.</time_frame>
    <description>- National Institutes of Health Stroke Scale (NIHSS) at discharge and 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological status; Modified Rankin Scale (mRS) Assessment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4 and 5 years.</time_frame>
    <description>- Modified Rankin Scale (mRS) at discharge and all follow-up visits through 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological status; Neurological physical exam assessment</measure>
    <time_frame>Participants will be followed for the duration of the trial, through 10 years.</time_frame>
    <description>- Neurological physical exam in all subjects where stroke is suspected</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Status; Kansas City Cardiomyopathy Quality of Life questionnaire Assessment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 1 and 5 years.</time_frame>
    <description>Evaluated by Kansas City Cardiomyopathy Quality of Life questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Status; SF-12 Quality of Life questionnaire Assessment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 1 and 5 years.</time_frame>
    <description>Evaluated by SF-12 Quality of Life questionnaire</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">630</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>ACURATE Valve - Randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACURATE Valve - Single-arm Roll-in</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Commercial Valve - Randomized</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System
Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACURATE neo2™ Transfemoral TAVR System</intervention_name>
    <description>Symetis ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).</description>
    <arm_group_label>ACURATE Valve - Randomized</arm_group_label>
    <arm_group_label>ACURATE Valve - Single-arm Roll-in</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CoreValve TAVR System</intervention_name>
    <description>Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).</description>
    <arm_group_label>Commercial Valve - Randomized</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards SAPIEN 3 TAVR System</intervention_name>
    <description>Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)</description>
    <arm_group_label>Commercial Valve - Randomized</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IC1. Subject has documented severe symptomatic native aortic stenosis defined as
             follows: aortic valve area (AVA) ≤1.0 cm2 (or AVA index ≤0.6 cm2/m2) AND a mean
             pressure gradient ≥40 mmHg, OR maximal aortic valve velocity ≥4.0 m/s, OR Doppler
             velocity index ≤0.25 as measured by echocardiography and/or invasive hemodynamics.

        Note: In cases of low flow, low gradient aortic stenosis with left ventricular dysfunction
        (ejection fraction &lt;50%), dobutamine can be used to assess the grade of aortic stenosis
        (maximum dobutamine dose of 20 mcg/kg/min recommended); the subject may be enrolled if
        echocardiographic criteria are met with this augmentation.

          -  IC2. Subject has a documented aortic annulus size of ≥21 mm and ≤27 mm based on the
             center's assessment of pre-procedure diagnostic imaging (and confirmed by the Case
             Review Committee [CRC]) and, for the randomized cohort, is deemed treatable with an
             available size of both test and control device.

          -  IC3. For subjects with symptomatic aortic valve stenosis per IC1 definition above,
             functional status is NYHA Functional Class ≥ II.

          -  IC4. Heart team (which must include an experienced cardiac interventionalist and an
             experienced cardiac surgeon) agrees that the subject is at intermediate risk or above
             for surgical valve replacement and TAVR is appropriate. Heart team should consider the
             STS score as well as other factors including frailty, prior surgical history,
             malignancy or radiation therapy, deformity, and aortic calcification. Subjects
             considered to be at intermediate risk or above have a predicted risk of surgical
             mortality ≥ 3% based on the STS risk score and other clinical comorbidities unmeasured
             by the STS risk calculator.

        Note 1: Risk of operative mortality must be assessed via an in-person evaluation by a
        center cardiac surgeon and must be confirmed by the CRC (which must include an experienced
        cardiac surgeon).

        Note 2: At the time this protocol was written, subjects at extreme and high surgical risk
        were approved for TAVR with commercially available devices in the United States and Canada.
        Subjects at intermediate surgical risk were approved for TAVR with select commercially
        available devices in the United States and Canada. Subjects at low surgical risk were
        subsequently approved for TAVR with commercially available devices in the United States.

          -  IC5. Heart team (which must include an experienced cardiac interventionalist and an
             experienced cardiac surgeon) agrees that the subject is likely to benefit from valve
             replacement.

          -  IC6. Subject (or legal representative) understands the study requirements and the
             treatment procedures, and provides written informed consent.

          -  IC7. Subject, family member, and/or legal representative agree(s) and subject is
             capable of returning to the study hospital for all required scheduled follow up
             visits.

          -  IC8. Subject is expected to be able to take the protocol-required adjunctive
             pharmacologic therapy.

        Exclusion Criteria:

          -  EC1. Subject has a unicuspid or bicuspid aortic valve.

          -  EC2. Subject has had an acute myocardial infarction within 30 days prior to the index
             procedure (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice
             normal in the presence of CK-MB elevation and/or troponin elevation).

          -  EC3. Subject has had a cerebrovascular accident or transient ischemic attack
             clinically confirmed by a neurologist or neuroimaging within the past 6 months prior
             to study enrollment.

          -  EC4. Subject is on renal replacement therapy or has eGFR &lt;20.

          -  EC5. Subject has a pre-existing prosthetic aortic or mitral valve.

          -  EC6. Subject has severe (4+) aortic, tricuspid, or mitral regurgitation.

          -  EC7. Subject has moderate or severe mitral stenosis (mitral valve area ≤1.5 cm2 and
             diastolic pressure half-time ≥150 ms, Stage C or D76).

          -  EC8. Subject has a need for emergency surgery for any reason.

          -  EC9. Subject has a history of endocarditis within 6 months of index procedure or
             evidence of an active systemic infection or sepsis.

          -  EC10. Subject has echocardiographic evidence of new intra-cardiac vegetation or
             intraventricular or paravalvular thrombus requiring intervention.

          -  EC11. Subject has platelet count &lt;50,000 cells/mm3 or &gt;700,000 cells/mm3, or white
             blood cell count &lt;1,000 cells/mm3.

          -  EC12. Subject has had a gastrointestinal bleed requiring hospitalization or
             transfusion within the past 3 months, or has other clinically significant bleeding
             diathesis or coagulopathy that would preclude treatment with required antiplatelet
             regimen, or will refuse transfusions.

          -  EC13. Subject has known hypersensitivity to contrast agents that cannot be adequately
             pre-medicated, or has known hypersensitivity to the protocol required medications
             (aspirin, all P2Y12 inhibitors, heparin), or to the individual components of the test
             or control valve (nickel, titanium, stainless steel, platinum, iridium or polyethylene
             terephthalate [PET]).

          -  EC14. Subject has a life expectancy of less than 12 months due to non-cardiac,
             comorbid conditions based on the assessment of the investigator at the time of
             enrollment.

          -  EC15. Subject has hypertrophic cardiomyopathy.

          -  EC16. Subject has any therapeutic invasive cardiac or vascular procedure within 30
             days prior to the index procedure (except for balloon aortic valvuloplasty, pacemaker
             implantation, or implantable cardioverter defibrillator implantation, which are
             allowed).

          -  EC17. Subject has untreated coronary artery disease, which in the opinion of the
             treating physician is clinically significant and requires revascularization.

          -  EC18. Subject has severe left ventricular dysfunction with ejection fraction &lt;20%.

          -  EC19. Subject is in cardiogenic shock or has hemodynamic instability requiring
             inotropic support or mechanical support devices.

          -  EC20. Subject has arterial access that is not acceptable for the study device (test or
             control) delivery systems as defined in the device (test or control) Directions For
             Use.

          -  EC21. Subject has either of the following:

               -  Severe vascular disease that would preclude safe access (e.g., aneurysm with
                  thrombus that cannot be crossed safely; marked tortuosity; significant narrowing
                  of the abdominal aorta; severe unfolding of the thoracic aorta; or thick,
                  protruding, ulcerated atheroma in the aortic arch), OR

               -  Severe/eccentric calcification of the aortic annulus that would prevent safe
                  implantation of the TAVR prosthesis.

          -  EC22. Subject has current problems with substance abuse (e.g., alcohol, etc.) that may
             interfere with the subject's participation in this study.

          -  EC23. Subject is participating in another investigational drug or device study that
             has not reached its primary endpoint or subject intends to participate in another
             investigational device clinical trial within 12 months after index procedure.

          -  EC24. Subject has untreated conduction system disorder (e.g., Type II second degree
             atrioventricular block) that in the opinion of the treating physician is clinically
             significant and requires a pacemaker implantation. Enrollment is permissible after
             permanent pacemaker implantation.

          -  EC25. Subject has severe incapacitating dementia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj R. Makkar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J. Reardon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist DeBakey Heart &amp; Vascular Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Currier</last_name>
    <phone>508-683-4927</phone>
    <email>Lisa.Currier@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Gregory Von Mering, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Good Samaritan</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Ashish Pershad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>David Rizik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Paul Teirstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Raj R Makkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Jeffrey Southard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Rassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Rahul Sharma, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Joshua D Rovin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Vijaykumar Kasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Christopher Meduri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital (Midtown)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Chandan Devireddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Ravi Ramana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital (Prairie)</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Nilesh Goswami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>James Hermiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Phillip Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>John Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio Inglessis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Tsuyoshi Kaneko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Nikos Kakouros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Stanley Chetcuti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>William O'Neill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Santiago Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital-St. Paul</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Mudassar Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Marc Sintek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Kintur Sanghvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Mark Russo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Sanjay Samy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore-Jack D. Weiler Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Mohamed Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaleida Health</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Vijay Iyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Annapoorna Kini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell Presbyterian - New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Chiu Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>George Petrossian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>John Vavalle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Michael Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>David Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lindner Center for Research and Education at Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Dean Kereiakes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Samir Kapadia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Columbus Cardiology Consultants</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Noah Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research and Innovation Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Steven Yakubov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>George Chrysant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC - Pinnacle</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Hemal Gada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Eric Gnall, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Thomas Ascension</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Morse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Robert Stoler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>James Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Neil Kleiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Regional Medical Center at Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Srinivasa Potluri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Harold Dauerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Paul Mahoney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Health System</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Basel Ramlawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Apurva Badheka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Albert Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Health - St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>John Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Pantelis Diamantouros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Shaym Radhakrishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Jeannot Potvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Reda Ibrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

